These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25528216)

  • 21. Truncation of the C-terminus of human MLH1 blocks intracellular stabilization of PMS2 and disrupts DNA mismatch repair.
    Mohd AB; Palama B; Nelson SE; Tomer G; Nguyen M; Huo X; Buermeyer AB
    DNA Repair (Amst); 2006 Mar; 5(3):347-61. PubMed ID: 16338176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interdependence of DNA mismatch repair proteins MLH1 and MSH2 in apoptosis in human colorectal carcinoma cell lines.
    Hassen S; Ali AA; Kilaparty SP; Al-Anbaky QA; Majeed W; Boman BM; Fields JZ; Ali N
    Mol Cell Biochem; 2016 Jan; 412(1-2):297-305. PubMed ID: 26728996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An intact Pms2 ATPase domain is not essential for male fertility.
    Fischer JM; Dudley S; Miller AJ; Liskay RM
    DNA Repair (Amst); 2016 Mar; 39():46-51. PubMed ID: 26753533
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Chiang YC; Park IY; Terzo EA; Tripathi DN; Mason FM; Fahey CC; Karki M; Shuster CB; Sohn BH; Chowdhury P; Powell RT; Ohi R; Tsai YS; de Cubas AA; Khan A; Davis IJ; Strahl BD; Parker JS; Dere R; Walker CL; Rathmell WK
    Cancer Res; 2018 Jun; 78(12):3135-3146. PubMed ID: 29724720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification.
    Parsons MT; Buchanan DD; Thompson B; Young JP; Spurdle AB
    J Med Genet; 2012 Mar; 49(3):151-7. PubMed ID: 22368298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Germline MLH1 Mutations Are Frequently Identified in Lynch Syndrome Patients With Colorectal and Endometrial Carcinoma Demonstrating Isolated Loss of PMS2 Immunohistochemical Expression.
    Dudley B; Brand RE; Thull D; Bahary N; Nikiforova MN; Pai RK
    Am J Surg Pathol; 2015 Aug; 39(8):1114-20. PubMed ID: 25871621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).
    Maldonado E; Rathmell WK; Shapiro GI; Takebe N; Rodon J; Mahalingam D; Trikalinos NA; Kalebasty AR; Parikh M; Boerner SA; Balido C; Krings G; Burns TF; Bergsland EK; Munster PN; Ashworth A; LoRusso P; Aggarwal RR
    Cancer Res Commun; 2024 Jul; 4(7):1793-1801. PubMed ID: 38920407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.
    Liao L; Testa JR; Yang H
    Cancer Genet; 2015 May; 208(5):206-14. PubMed ID: 25873528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apoptosis and mutation in the murine small intestine: loss of Mlh1- and Pms2-dependent apoptosis leads to increased mutation in vivo.
    Sansom OJ; Bishop SM; Court H; Dudley S; Liskay RM; Clarke AR
    DNA Repair (Amst); 2003 Sep; 2(9):1029-39. PubMed ID: 12967659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.
    Skeldon SC; Semotiuk K; Aronson M; Holter S; Gallinger S; Pollett A; Kuk C; van Rhijn B; Bostrom P; Cohen Z; Fleshner NE; Jewett MA; Hanna S; Shariat SF; Van Der Kwast TH; Evans A; Catto J; Bapat B; Zlotta AR
    Eur Urol; 2013 Feb; 63(2):379-85. PubMed ID: 22883484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma.
    Piva F; Giulietti M; Occhipinti G; Santoni M; Massari F; Sotte V; Iacovelli R; Burattini L; Santini D; Montironi R; Cascinu S; Principato G
    Oncotarget; 2015 Oct; 6(31):32161-8. PubMed ID: 26452128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes.
    Xie Y; Sahin M; Sinha S; Wang Y; Nargund AM; Lyu Y; Han S; Dong Y; Hsieh JJ; Leslie CS; Cheng EH
    Nat Cancer; 2022 Feb; 3(2):188-202. PubMed ID: 35115713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects.
    Simon JM; Hacker KE; Singh D; Brannon AR; Parker JS; Weiser M; Ho TH; Kuan PF; Jonasch E; Furey TS; Prins JF; Lieb JD; Rathmell WK; Davis IJ
    Genome Res; 2014 Feb; 24(2):241-50. PubMed ID: 24158655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA mismatch repair gene MLH1 induces apoptosis in prostate cancer cells.
    Fukuhara S; Chang I; Mitsui Y; Chiyomaru T; Yamamura S; Majid S; Saini S; Hirata H; Deng G; Gill A; Wong DK; Shiina H; Nonomura N; Dahiya R; Tanaka Y
    Oncotarget; 2014 Nov; 5(22):11297-307. PubMed ID: 25526032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Correlation between mismatch-repair protein expression and clinicopathologic features in 658 colorectal cancers].
    Hu XR; Xu C; Kang Y; Wang T; Zhang Y; Yang XH
    Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):827-833. PubMed ID: 30423605
    [No Abstract]   [Full Text] [Related]  

  • 36. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
    Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY
    Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint.
    Carvalho S; Vítor AC; Sridhara SC; Martins FB; Raposo AC; Desterro JM; Ferreira J; de Almeida SF
    Elife; 2014 May; 3():e02482. PubMed ID: 24843002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma.
    Duns G; van den Berg E; van Duivenbode I; Osinga J; Hollema H; Hofstra RM; Kok K
    Cancer Res; 2010 Jun; 70(11):4287-91. PubMed ID: 20501857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multilevel Regulation of β-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma.
    Rao H; Li X; Liu M; Liu J; Feng W; Tang H; Xu J; Gao WQ; Li L
    Cancer Res; 2021 Jul; 81(13):3554-3567. PubMed ID: 33910928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MLH1 function is context dependent in colorectal cancers.
    Jackson T; Ahmed MA; Seth R; Jackson D; Ilyas M
    J Clin Pathol; 2011 Feb; 64(2):141-5. PubMed ID: 21169277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.